| Title |
Double-blind, placebo-controlled, two-period, crossover trial to examine the pharmacokinetics of lisdexamfetamine dimesylate in healthy older adults
|
|---|---|
| Published in |
Neuropsychiatric Disease and Treatment, February 2013
|
| DOI | 10.2147/ndt.s38377 |
| Pubmed ID | |
| Authors |
James Ermer, Mary B Haffey, Cynthia Richards, Kenneth Lasseter, Ben Adeyi, Mary Corcoran, Beverly Stanton, Patrick Martin |
| Abstract |
Pharmacokinetic and safety data on stimulants in older adults are limited. The objective of this study was to characterize the pharmacokinetics of lisdexamfetamine dimesylate (LDX), a d-amphetamine prodrug, in older adults. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 30 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 2 | 7% |
| United States | 1 | 3% |
| Unknown | 27 | 90% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 5 | 17% |
| Researcher | 4 | 13% |
| Student > Master | 3 | 10% |
| Student > Bachelor | 2 | 7% |
| Student > Doctoral Student | 2 | 7% |
| Other | 5 | 17% |
| Unknown | 9 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 23% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 10% |
| Agricultural and Biological Sciences | 2 | 7% |
| Psychology | 2 | 7% |
| Nursing and Health Professions | 1 | 3% |
| Other | 2 | 7% |
| Unknown | 13 | 43% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 March 2013.
All research outputs
#20,823,121
of 25,584,565 outputs
Outputs from Neuropsychiatric Disease and Treatment
#2,293
of 3,120 outputs
Outputs of similar age
#230,894
of 292,111 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#25
of 39 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,120 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one is in the 18th percentile – i.e., 18% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 292,111 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 10th percentile – i.e., 10% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 39 others from the same source and published within six weeks on either side of this one. This one is in the 35th percentile – i.e., 35% of its contemporaries scored the same or lower than it.